Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Pharmaceutical Poisoning: Treatment Strategies

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Managing Dermatologic Delusional Disorders: A US Psychodermatology Perspective for Clinicians.

CNS drugs·2026

Same author

The Role of the Vagus Nerve and Its Stimulation in Modulating Inflammatory Skin Diseases and Other Dermatologic Conditions: From Mechanisms to Therapeutics.

Dermatology (Basel, Switzerland)·2026

Same author

Vagus Nerve Stimulation Reduces Cutaneous Inflammation and Proinflammatory Cytokines in Murine Models of Psoriasis and Atopic Dermatitis.

Experimental dermatology·2026

Same author

Patient Characteristics and Treatment Approaches in Delusional Infestation Across Two Medical Centers: A Retrospective Study.

Skin (Milwood, N.Y.)·2026

Same author

Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium.

American journal of clinical dermatology·2026

Same author

Treatment of recurrent facial ulcerations and dysesthesias from trigeminal trophic syndrome with chronic transcutaneous vagus nerve stimulation.

JAAD case reports·2026

Search research articles

Related Experiment Videos

Efalizumab discontinuation: a practical strategy.

Rupa Pugashetti¹, John Koo

¹Department of Dermatology, University of California, San Francisco, CA 94118, USA.

The Journal of Dermatological Treatment

|May 22, 2009

Summary

This summary is machine-generated.

Efalizumab withdrawal necessitates alternative plaque psoriasis treatments. Cyclosporine is recommended to prevent potential efalizumab-associated psoriasis rebound, offering a practical transition strategy.

Related Experiment Videos

Area of Science:

Immunodermatology
Neuroimmunology

Background:

Efalizumab, a monoclonal antibody targeting T-cells, was used for plaque psoriasis.
Market withdrawal of efalizumab occurred due to progressive multifocal leukoencephalopathy (PML) concerns.

Purpose of the Study:

To provide guidance for transitioning patients from efalizumab to alternative therapies.
To address the potential for psoriasis rebound post-efalizumab discontinuation.

Main Methods:

Review of available literature on efalizumab and psoriasis management.
Clinical experience of authors in managing patients transitioning from efalizumab.

Main Results:

Psoriasis rebound is a significant concern after efalizumab cessation.
Cyclosporine, at a maximum dermatologic dose of 5 mg/kg/day, appears effective in preventing rebound.

Conclusions:

Transitioning patients from efalizumab requires careful management to mitigate psoriasis rebound.
Cyclosporine is a viable option for minimizing or preventing rebound in patients previously treated with efalizumab.